Boston Scientific upgraded by Deutsche Bank with a new price target
$BSX
Medical/Dental Instruments
Health Care
Deutsche Bank upgraded Boston Scientific from Hold to Buy and set a new price target of $108.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/16/2025 | $118.00 | Outperform | Leerink Partners |
| 4/16/2025 | $113.00 | Hold → Buy | Needham |
| 1/10/2025 | $108.00 | Hold → Buy | Deutsche Bank |
| 10/18/2024 | Buy → Hold | Needham | |
| 5/30/2024 | $90.00 | Buy | Goldman |
| 2/1/2024 | $65.00 → $80.00 | Neutral → Buy | Mizuho |
| 7/19/2023 | $59.00 | Outperform | Robert W. Baird |
| 6/30/2023 | $64.00 | Buy | CL King |
MARLBOROUGH, Mass., May 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will participate in two upcoming investor conferences in May. On May 13, 2025, Dan Brennan, executive vice president and chief financial officer, and Joe Fitzgerald, executive vice president and group president, Cardiology, will participate in a 30-minute question-and-answer session with the host analyst at Bank of America's 2025 Health Care Conference. The session will begin at approximately 8:00 a.m. PT / 11:00 a.m. ET. On May 28, 2025, Mike Mahoney, chairman and chief executive officer,
MARLBOROUGH, Mass., April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced that Dan Brennan, executive vice president and chief financial officer, has elected to retire following nearly 30 successful years with the company. Brennan will transition out of the chief financial officer position at the end of June and is expected to remain with Boston Scientific as a senior advisor through early October 2025. "I thank Dan for his incredible leadership and tremendous contributions to Boston Scientific," said Mike Mahoney, chairman and chief executi
MARLBOROUGH, Mass., April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $4.663 billion during the first quarter of 2025, growing 20.9 percent on a reported basis, 22.2 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $674 million or $0.45 per share (EPS), compared to $495 million or $0.33 per share a year ago, and achieved adjusted3 EPS of $0.75 for the period, compared to $0.56 a year ago.
For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide